REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
2.070 USD    0.00%
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
06/28Wall Street Set to Open Higher
MT
06/28Top Premarket Decliners
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Regulus Therapeutics' Shares Surge After FDA Accepts Investigational New Drug Application for Kidney Disease Treatment

05/11/2022 | 12:55pm EDT


© MT Newswires 2022
All news about REGULUS THERAPEUTICS INC.
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
06/28Wall Street Set to Open Higher
MT
06/28Top Premarket Decliners
MT
06/27REGULUS THERAPEUTICS INC. : Material Modification to Rights of Security Holders, Financial..
AQ
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
PR
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
CI
06/21Regulus Therapeutics Gets FDA Orphan Designation for RGLS8429
DJ
06/13REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/13Regulus Reports First Individual Dosed in Early-Stage Single-Ascending Dose Trial of RG..
MT
06/13Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SA..
PR
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -27,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,06x
Yield 2022 -
Capitalization 30,2 M 30,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 9,67x
Nbr of Employees 25
Free-Float 9,47%
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 2,07 $
Average target price 15,00 $
Spread / Average Target 625%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-34.29%30
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-7.99%44 566
BIONTECH SE-38.91%38 276